256940 — Keeps BioPharma Income Statement

0.000.00%

Last trade - 00:00

TechnologyHighly SpeculativeSmall CapNeutral

Annual income statement for Keeps BioPharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	15,217	4,261	14,617	92,133	127,583
Cost of Revenue
Gross Profit	3,947	-789	1,044	12,798	17,240
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	15,604	16,568	22,379	80,954	121,364
Operating Profit	-387	-12,307	-7,762	11,179	6,219
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-2,276	-17,305	-13,877	5,372	3,370
Provision for Income Taxes
Net Income After Taxes	-2,547	-16,231	-12,040	3,463	1,612
Minority Interest
Net Income Before Extraordinary Items
Net Income	-2,406	-15,317	-11,375	3,930	1,113
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-2,406	-15,317	-11,375	3,930	1,113
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-161	-884	-639	-74.1	58.7
Dividends per Share